Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis reports positive data from heart disease drug study

Novartis reports positive data from heart disease drug study

24th November 2014

Novartis has reported data on a new analysis of its investigational medicine LCZ696, showing its potential to change the course of heart disease for patients.

Nine new analyses of the drug have added to the growing body of evidence supporting its safety and efficacy, with results from the PARADIGM-HF study showing it was able to reduce the incidence of sudden deaths, emergency room visits, hospitalisations, worsening symptoms and need for more intense treatment in patients with heart failure with reduced ejection fraction (HFrEF).

Patients' and doctors' assessments of disease severity were also significantly better with LCZ696 than an alternative therapy, whereas the effects on certain heart biomarkers indicate that the drug was able to reduce cardiac stress and damage.

Novartis plans to file for marketing authorisation of the drug in the US by the end of 2014, with an EU submission planned for early 2015.

David Epstein, division head of Novartis Pharmaceuticals, said: "This therapy offers hope to millions of people living with HFrEF that they can also reduce or slow the decline in their heart function, potentially altering the progression of their disease."

Last week, the company announced clinical data showing the benefits its drug secukinumab can offer to psoriatic arthritis and ankylosing spondylitis patients.ADNFCR-8000103-ID-801761853-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.